The SR One VC unit of GlaxoSmithKline plc (ADR) (NYSE:GSK) has contributed in the Series C $39 million funding round of PsiOxus Therapeutics. The company is raising funds for conducting clinical trials of an oncolytic virus treatment with a checkpoint inhibitor. The fundraising has been initiated after the Phase 1 trial results of a study involving infusion of the oncolytic virus enadenotucirev that showed tumor cell infections
{iframe}http://wallstreetpr.com/glaxosmithkline-plc-adr-nysegsk-unit-invests-in-psioxus-therapeutics-39-million-fund-raising-36241{/iframe}